Citi sees limited legal risk for Kenvue (KVUE) after the President Trump discouraged pregnant women from taking acetaminophen, the active ingredient in Tylenol. However, there could be risk to Tylenol consumption given the negative headlines, the analyst tells investors in a research note. Citi sees Kenvue shares trading higher today following yesterday’s selloff given the lack of new scientific evidence presented by the Trump administration. The firm keeps a Neutral rating on the shares with a $20 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KVUE:
- Hold Rating for Kenvue, Inc. Amidst Market Reaction to Government Advisories on Acetaminophen
- Kenvue Stock (KVUE) Pops, Defying Trump’s Claim Linking Tylenol to Autism
- Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!
- Kenvue Stock (KVUE) Under Watch as Trump Team Eyes Tylenol–Autism Link
- Trump Trade: TikTok’s algorithm, data to be controlled ‘by America’